

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
24 November 2022 (24.11.2022)



(10) International Publication Number
WO 2022/242692 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 35/00 (2006.01)
A61K 45/00 (2006.01) A61P 43/00 (2006.01)
A61K 47/20 (2006.01)

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CN2022/093631

(22) International Filing Date:

18 May 2022 (18.05.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

202110559728.8 21 May 2021 (21.05.2021) CN

(71) Applicant: REMEGEN CO., LTD. [CN/CN]; 58 Middle Beijing Road Yantai Economic & Technological, Development Area, Yantai, Shandong 264006 (CN).

(72) Inventors: FANG, Jianmin; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN). JIANG, Jing; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN). LI, Shenjun; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN). SU, Xiaohong; 58 Middle Beijing Road Yantai, Economic & Technological, Development Area, Yantai, Shandong 264006 (CN).

(74) Agent: WU, FENG & ZHANG; 3 FL, Building 2, Yard 3, Fengxiuzhonglu Road, Haidian District, Beijing 100094 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

Declarations under Rule 4.17:

- of inventorship (Rule 4.17(iv))
- as to non-prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: USE OF ANTIBODY-DRUG CONJUGATE IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITOR IN TREATMENT OF UROTHELIAL CANCER

(57) Abstract: Provided is use of an antibody-drug conjugate targeting Her2 in combination with an immune checkpoint inhibitor such as PD-1 antibody or PD-L1 antibody, in the preparation of a medicine for treating patients with urothelial cancer, especially locally advanced or metastatic urothelial cancer. Compared to treatment with either of the two drugs alone, treatment with both in combination has a marked synergistic effect and significant therapeutic effect. In addition, the combination treatment had good efficacy for patients with low HER2 IHC expression (I+).

WO 2022/242692 A1